Oferlanz (Lisdexamfetamine Diadipate)

Lisdexamfetamine diadipate, the active ingredient in Oferlanz, is a central nervous system stimulant (amphetamine) presented as a oral medication for oral use. It treats attention deficit hyperactivity disorder and binge eating disorder in children, adolescents and adults.

GNH USA supplies Oferlanz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oferlanz is a stimulant that acts on neuro‑behavioral pathways associated with attention and impulse control. - Attention‑deficit/hyperactivity disorder (ADHD): Improves concentration, reduces hyperactivity and supports better executive functioning. - Binge‑eating disorder (BED): Decreases the frequency of binge episodes and helps regulate appetite control. - Narcolepsy (off‑label): May improve daytime wakefulness, though it is not a primary indication.

Adverse reactions to Oferlanz can range from mild to severe and should be monitored during therapy.

Common Side Effects: - Insomnia - Decreased appetite - Dry mouth - Headache - Irritability - Weight loss

Serious or Rare Side Effects: - Cardiovascular events (e.g., hypertension, tachycardia) - Psychiatric symptoms (e.g., psychosis, mania) - Severe allergic reactions - Growth suppression in children - Peripheral vasculitis - Seizures

Before prescribing Oferlanz, clinicians should evaluate cardiovascular health, psychiatric history and potential for misuse. - Cardiovascular assessment: Obtain baseline blood pressure and heart rate. - Psychiatric screening: Review history of psychosis, bipolar disorder or severe anxiety. - Substance‑use evaluation: Assess risk of abuse or diversion. - Growth monitoring: Track height and weight in pediatric patients. - Drug‑interaction review: Check concomitant medications that affect catecholamine pathways. - Store at ambient temperature: keep in original container, protect from moisture and light.

Oferlanz may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Mono‑Mono‑Mono  :            ...

Moderate  …